Nov 4, 2016 | Digital Pathology, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Testing, Management & Operations
Breakthrough method could provide pathologists with a less expensive alternative to high-priced super-resolution microscopes or often-imprecise microscopy software
Intriguing new research has the potential to “turbocharge” the standard medical laboratory microscope in ways that create a “super-vision” capability. This would give pathologists and medical researchers an inexpensive alternative to high-priced super-resolution microscopes or often-imprecise microscopy software.
Seeking a new method for counting molecules in complexes, researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University paired their DNA-powered super-resolution microscopy platform—DNA-PAINT and Exchange-PAINT—with a new procedure called quantitative points accumulation in nanoscale topography—or qPAINT. This new analytic tool can “count different molecular species in biological samples with high accuracy and precision,” noted a Wyss Institute press release. (more…)
Feb 10, 2014 | Instruments & Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Management & Operations
Pathologists and medical lab scientists may do more consults with interdisciplinary teams in connection with biomarker-based phase I clinical trial selection
Scientists are beginning to incorporate next-generation gene sequencing into a growing number of clinical trials. This is an important development because knowledge developed in clinical trials often forms the foundation for the evidence-based medicine guidelines issued following a successful clinical trial.
Further, these new uses for gene sequencing can directly lead to new opportunities for clinical laboratories and pathology groups. That’s because the increased use of gene sequencing for patients participating in clinical trials may well provide the necessary evidence to support new molecular diagnostics assays and genetic tests that physicians would use in support of therapeutic drugs cleared for market. (more…)
